XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Corrections to Previously Issued Consolidated Financial Statements (Details 1) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Jun. 30, 2017
Jun. 30, 2016
Jun. 30, 2017
Jun. 30, 2016
Sep. 30, 2016
Sep. 30, 2015
Consolidated Balance Sheet            
Due to related party $ 953,000   $ 953,000   $ 6,500,000  
Total liabilities 1,056,130   1,056,130   6,556,470  
Additional paid-in capital 10,746,464   10,746,464   4,733,461  
Accumulated deficit (12,008,288)   (12,008,288)   (11,323,401)  
Total equity (deficit) (1,048,077)   (1,048,077)   (6,379,118)  
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses 169,427 $ 289,098 562,930 $ 349,486    
Research and development expenses 17,500 67,848 10,000,000    
Net loss from operations (189,479) (289,098) (636,706) (10,349,518)    
Loss from continuing operations before income taxes (217,879) (292,401) (684,057) (10,352,769)    
Net Loss $ (217,879) $ (293,237) $ (684,887) $ (10,353,605)    
Basic and diluted loss per share $ (0.00) $ (0.00) $ (0.00) $ (0.05)    
Consolidated Statements of Cash Flow            
Net loss from operating activities $ (217,879) $ (293,237) $ (684,887) $ (10,353,605)    
Issuance of common stock for compensation          
(Decrease) increase in due to related party     (647,000) 6,477,483    
Net cash used in operating activities     (1,275,484) (3,263,340)    
Previously Reported on Form 10K [Member]            
Consolidated Balance Sheet            
Due to related party      
Total liabilities         56,470  
Additional paid-in capital 10,586,464   10,586,464   4,733,401  
Accumulated deficit (11,848,288) (669,207) (11,848,288) (669,207) (4,823,401)  
Total equity (deficit)         120,882  
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         4,497,263  
Research and development expenses        
Net loss from operations (99,479)   (476,706)   (4,497,295)  
Loss from continuing operations before income taxes (217,879)   (524,057)   (4,506,963)  
Net Loss (217,879)   (524,887) $ (353,605) $ (4,507,799)  
Basic and diluted loss per share       $ 0  
Consolidated Statements of Cash Flow            
Net loss from operating activities (217,879)   (524,887) $ (353,605) $ (4,507,799)  
Issuance of common stock for compensation         1,295,324  
(Decrease) increase in due to related party       (22,517) (22,517)  
Net cash used in operating activities     (1,115,484) (3,857,447)   $ (517)
Adjustments No.1 [Member]            
Consolidated Balance Sheet            
Due to related party   6,500,000   6,500,000 6,500,000  
Total liabilities         6,500,000  
Additional paid-in capital 160,000   160,000    
Accumulated deficit (160,000) (10,000,000) (160,000) (10,000,000) (6,500,000)  
Total equity (deficit)         (6,500,000)  
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         (3,500,060)  
Research and development expenses     10,000,000   10,000,000  
Net loss from operations (90,000)   (160,000)   (6,499,940)  
Loss from continuing operations before income taxes (90,000)   (160,000)   (6,499,940)  
Net Loss (90,000)   (160,000) $ (10,000,000) $ (6,499,940)  
Basic and diluted loss per share       $ (0.05) $ (0.06)  
Consolidated Statements of Cash Flow            
Net loss from operating activities (90,000)   (160,000) $ (10,000,000) $ (6,499,940)  
Issuance of common stock for compensation         (60)  
(Decrease) increase in due to related party       6,500,000 6,500,000  
Net cash used in operating activities     (160,000) 594,107  
Adjustments No.2 [Member]            
Consolidated Balance Sheet            
Due to related party          
Total liabilities          
Additional paid-in capital         60  
Accumulated deficit          
Total equity (deficit)          
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         60  
Research and development expenses          
Net loss from operations         (60)  
Loss from continuing operations before income taxes         (60)  
Net Loss         $ (60)  
Basic and diluted loss per share         $ 0  
Consolidated Statements of Cash Flow            
Net loss from operating activities         $ (60)  
Issuance of common stock for compensation         60  
(Decrease) increase in due to related party          
Net cash used in operating activities           (198)
Restated [Member]            
Consolidated Balance Sheet            
Due to related party   6,500,000   6,500,000 6,500,000  
Total liabilities         6,556,470  
Additional paid-in capital 10,746,464   10,746,464   4,733,461  
Accumulated deficit (12,008,288) $ (10,669,207) (12,008,288) (10,669,207) (11,323,401)  
Total equity (deficit)         (6,379,118)  
Consolidated Statements of Operations and Comprehensive Loss            
Selling, general and administrative expenses         997,263  
Research and development expenses     10,000,000   10,000,000  
Net loss from operations (189,479)   (636,706)   (10,997,295)  
Loss from continuing operations before income taxes (217,879)   (684,057)   (11,006,963)  
Net Loss (217,879)   (684,887) $ (10,353,605) $ (11,007,799)  
Basic and diluted loss per share       $ (0.05) $ (0.06)  
Consolidated Statements of Cash Flow            
Net loss from operating activities $ (217,879)   (684,887) $ (10,353,605) $ (11,007,799)  
Issuance of common stock for compensation         1,295,324  
(Decrease) increase in due to related party       6,477,483 $ 6,477,483  
Net cash used in operating activities     $ (1,275,484) $ (3,263,340)   $ (715)